RecruitingCutaneous MelanomaSynovial Sarcoma
ACTengine® IMA203 Combined With mRNA-4203
Eligible age
18+ yrs
Accepts
All genders
Locations
4 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This purpose of this clinical trial is to evaluate the safety, tolerability and anti-tumor activity of IMA203 in combination with different doses of mRNA-4203. The trial includes participants with previously treated unresectable or metastatic cutaneous melanoma (CM) or synovial sarcoma (SS).
Sponsor: Immatics US, Inc.
You may qualify if…
- ✓ Pathologically confirmed and documented cutaneous melanoma (CM) or synovial sarcoma (SS) with unresectable or metastatic disease
- ✓ HLA-A\*02:01 positive
- ✓ Adequate selected organ function per protocol
- ✓ Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- ✓ Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1)
- ✓ Life expectancy more than 5 months
- ✓ CM participants who must have disease progression (resistance, toxicity) on or after at least one PD-1 inhibitor
- ✓ SS participants must have received (or declined) at least one line of treatment (including SoC) and are still in need of further systemic therapy.
You may not qualify if…
- ✕ History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within the last 3 years
- ✕ Pregnant or breastfeeding
- ✕ Serious autoimmune disease
- ✕ History of cardiac conditions as per protocol
- ✕ Prior allogenic stem cell transplantation or solid organ transplantation
- ✕ Concurrent severe and/or uncontrolled medical disease that could compromise participation in the study
- ✕ History of hypersensitivity to cyclophosphamide, fludarabine, or IL-2
- ✕ History of hypersensitivity to mRNA-based medicines
Where it's recruiting
Source: ClinicalTrials.gov · NCT06946225 · last updated 2026-01-08